These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 31357122)

  • 1. B cell depletion therapy resulting in sustained remission of severe autoimmune complications following Alemtuzumab treatment of Multiple Sclerosis.
    Massey J; Barnett Y; Curnow J; Sutton I
    Mult Scler Relat Disord; 2019 Oct; 35():100-103. PubMed ID: 31357122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitigating alemtuzumab-associated autoimmunity in MS: A "whack-a-mole" B-cell depletion strategy.
    Meltzer E; Campbell S; Ehrenfeld B; Cruz RA; Steinman L; Parsons MS; Zamvil SS; Frohman EM; Frohman TC
    Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 32769201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoimmune encephalitis following alemtuzumab treatment of multiple sclerosis.
    Giarola B; Massey J; Barnett Y; Rodrigues M; Sutton I
    Mult Scler Relat Disord; 2019 Feb; 28():31-33. PubMed ID: 30553166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquired haemophilia A as a secondary autoimmune disease after alemtuzumab treatment in multiple sclerosis: A case report.
    Pisa M; Della Valle P; Coluccia A; Martinelli V; Comi G; D'Angelo A; Moiola L
    Mult Scler Relat Disord; 2019 Jan; 27():403-405. PubMed ID: 30513503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab.
    Wiendl H; Carraro M; Comi G; Izquierdo G; Kim HJ; Sharrack B; Tornatore C; Daizadeh N; Chung L; Jacobs AK; Hogan RJ; Wychowski LV; Van Wijmeersch B;
    Neurol Neuroimmunol Neuroinflamm; 2020 Jan; 7(1):. PubMed ID: 31662412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired haemophilia A complicating alemtuzumab therapy for multiple sclerosis.
    McCaughan G; Massey J; Sutton I; Curnow J
    BMJ Case Rep; 2017 Dec; 2017():. PubMed ID: 29212866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoimmune thyroid disease following treatment with alemtuzumab for multiple sclerosis.
    Alamo A; Condorelli RA; La Vignera S; Calogero AE
    Int J Immunopathol Pharmacol; 2019; 33():2058738419843690. PubMed ID: 30968726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis.
    Phelps R; Winston JA; Wynn D; Habek M; Hartung HP; Havrdová EK; Markowitz GS; Margolin DH; Rodriguez CE; Baker DP; Coles AJ
    Mult Scler; 2019 Aug; 25(9):1273-1288. PubMed ID: 30986126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment.
    Baker D; Giovannoni G; Schmierer K
    Mult Scler Relat Disord; 2017 Nov; 18():181-183. PubMed ID: 29141806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.
    Meunier B; Rico A; Seguier J; Boutiere C; Ebbo M; Harle JR; Schleinitz N; Pelletier J
    Mult Scler; 2018 May; 24(6):811-813. PubMed ID: 29359614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous early-onset severe autoimmune hemolytic anemia and albuminuria during alemtuzumab treatment for multiple sclerosis.
    di Ioia M; Farina D; di Tommaso V; Travaglini D; Pietrolongo E; Onofrj M; de Luca G
    Mult Scler; 2018 May; 24(6):813-815. PubMed ID: 29359617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosis.
    Wehrum T; Beume LA; Stich O; Mader I; Mäurer M; Czaplinski A; Weiller C; Rauer S
    Neurology; 2018 Feb; 90(7):e601-e605. PubMed ID: 29352101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
    von Kutzleben S; Pryce G; Giovannoni G; Baker D
    Immunology; 2017 Apr; 150(4):444-455. PubMed ID: 27925187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pneumonitis secondary to alemtuzumab in a patient with multiple sclerosis - A non-infectious cause of breathlessness.
    Whiteside D; Barth S; Datta A; Trip SA
    Mult Scler Relat Disord; 2018 May; 22():139-140. PubMed ID: 29684788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutropenia following immune-depletion, notably CD20 targeting, therapies in multiple sclerosis.
    Baker D; Kang AS; Giovannoni G; Schmierer K
    Mult Scler Relat Disord; 2024 Feb; 82():105400. PubMed ID: 38181696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alemtuzumab treatment of multiple sclerosis in real-world clinical practice: A report from a single Italian center.
    di Ioia M; Di Stefano V; Farina D; Di Tommaso V; Travaglini D; Pietrolongo E; Sensi SL; Onofrj M; De Luca G
    Mult Scler Relat Disord; 2020 Feb; 38():101504. PubMed ID: 31733426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Refractory chronic spontaneous urticaria after the use of alemtuzumab in multiple sclerosis.
    Hu H; Reddell S; Riminton S; Chan C; Urriola N
    Neurol Neuroimmunol Neuroinflamm; 2020 Jan; 7(2):. PubMed ID: 31915266
    [No Abstract]   [Full Text] [Related]  

  • 18. Immune profiling of a patient with alemtuzumab-associated progressive multifocal leukoencephalopathy.
    Gerevini S; Capra R; Bertoli D; Sottini A; Imberti L
    Mult Scler; 2019 Jul; 25(8):1196-1201. PubMed ID: 30964396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoimmune hemolytic anemia, demyelinating relapse, and AQP1 antibodies after alemtuzumab infusion.
    Tzartos JS; Valsami S; Tzanetakos D; Stergiou C; Dandoulaki M; Barbarousi D; Psimenou E; Velonakis G; Stefanis L; Kilidireas K
    Neurol Neuroimmunol Neuroinflamm; 2020 May; 7(3):. PubMed ID: 32241823
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunological consequences of "immune reconstitution therapy" in multiple sclerosis: A systematic review.
    Sellner J; Rommer PS
    Autoimmun Rev; 2020 Apr; 19(4):102492. PubMed ID: 32062028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.